Dr. Reddy's Laboratories, a pharmaceutical company, agreed to acquire nicotine replacement therapy business from Haleon, a consumer healthcare company, for £500m. "The divestment of Haleon's NRT business outside of the US is a further example of Haleon being proactive in managing its portfolio and is consistent with our strategy as we implement change to become more agile and competitive. Whilst this business has great brands, these are not core for us, but I'm sure they will continue to flourish given the focus and capability of Dr Reddy's," Brian McNamara, Haleon Chief Executive Officer.